Squadron Capital Management LLC 13F holdings, Q2 2026
Holdings as of June 30, 2026 · filings on SEC EDGAR · this is the latest filing on record
Squadron Capital Management LLC disclosed 34 US equity positions worth $292.1m in its Q2 2026 13F filing. The largest position was RLMD at 17.4% of the reported book, followed by CCCC and COGT. Against the Q1 2026 filing, it opened 17 new positions, added to 9 and reduced 6 among the top 34 holdings.
What did Squadron Capital Management LLC own in Q2 2026? Top 34 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2026 |
|---|---|---|---|---|---|---|---|
| 1 | RLMD RELMADA THERAPEUTICS INC | Healthcare | 17.4% | $50.9m | 7,350,000 | -13% | reduced |
| 2 | CCCC C4 THERAPEUTICS INC | Healthcare | 11.5% | $33.6m | 7,200,000 | 220% | added |
| 3 | COGT COGENT BIOSCIENCES INC | Healthcare | 11.5% | $33.5m | 865,000 | 10% | added |
| 4 | KOD KODIAK SCIENCES INC | Healthcare | 6.7% | $19.5m | 500,000 | 32% | added |
| 5 | RLAY RELAY THERAPEUTICS INC | Healthcare | 6.2% | $18.1m | 970,000 | 44% | added |
| 6 | ZNTL ZENTALIS PHARMACEUTICALS INC | Healthcare | 6.1% | $17.9m | 3,700,000 | 2% | added |
| 7 | EWTX EDGEWISE THERAPEUTICS INC | Healthcare | 4.0% | $11.8m | 290,000 | -17% | reduced |
| 8 | MAZE MAZE THERAPEUTICS INC | Healthcare | 3.4% | $10.0m | 335,000 | 30% | added |
| 9 | IVA INVENTIVA SA | 3.2% | $9.2m | 2,435,000 | 355% | added | |
| 10 | ANL ADLAI NORTYE LTD | 3.0% | $8.8m | 764,876 | -40% | reduced | |
| 11 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 2.8% | $8.1m | 160,000 | – | new |
| 12 | PALI PALISADE BIO INC | Healthcare | 2.1% | $6.3m | 3,000,000 | 0% | held |
| 13 | IKT INHIBIKASE THERAPEUTICS INC | 2.1% | $6.1m | 3,000,000 | -14% | reduced | |
| 14 | ADAG ADAGENE INC | 1.8% | $5.2m | 1,250,000 | – | new | |
| 15 | FBRX FORTE BIOSCIENCES INC | 1.6% | $4.8m | 225,000 | – | new | |
| 16 | INFLARX NV | 1.5% | $4.5m | 2,000,000 | – | new | |
| 17 | ASMB ASSEMBLY BIOSCIENCES INC | Healthcare | 1.5% | $4.4m | 160,000 | – | new |
| 18 | PROMIS NEUROSCIENCES INC | 1.5% | $4.3m | 324,977 | 0% | held | |
| 19 | CTNM CONTINEUM THERAPEUTICS INC | 1.5% | $4.3m | 260,000 | – | new | |
| 20 | CMPS COMPASS PATHWAYS PLC | Healthcare | 1.5% | $4.2m | 300,000 | – | new |
| 21 | DFTX DEFINIUM THERAPEUTICS INC | Healthcare | 1.4% | $4.0m | 85,000 | – | new |
| 22 | SOL-GEL TECHNOLOGIES LTD | 1.3% | $3.9m | 52,000 | 68% | added | |
| 23 | BIOA BIOAGE LABS INC | 1.3% | $3.8m | 155,000 | – | new | |
| 24 | SCYX SCYNEXIS INC | 1.1% | $3.1m | 756,884 | – | new | |
| 25 | PROQR THRAPEUTICS N V | 1.0% | $2.8m | 1,511,496 | – | new | |
| 26 | RZLT REZOLUTE INC | 0.7% | $2.1m | 403,410 | – | new | |
| 27 | LPCN LIPOCINE INC NEW | 0.7% | $2.1m | 810,000 | 80% | added | |
| 28 | CUE CUE BIOPHARMA INC | 0.5% | $1.6m | 50,000 | – | new | |
| 29 | CALC CALCIMEDICA INC | 0.4% | $1.3m | 1,244,864 | – | new | |
| 30 | QUINCE THERAPEUTICS INC | 0.3% | $734.4k | 40,375 | – | new | |
| 31 | KTTA PASITHEA THERAPEUTICS CORP | 0.2% | $515.4k | 1,000,000 | -52% | reduced | |
| 32 | INM INMED PHARMACEUTICALS INC | 0.2% | $503.8k | 325,000 | – | new | |
| 33 | NMRA NEUMORA THERAPEUTICS INC. | Healthcare | 0.1% | $170.0k | 100,000 | – | new |
| 34 | NXTC NEXTCURE INC | 0.0% | $103.1k | 64,464 | -76% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.